ATN-161 is an investigational drug.
There have been 27 clinical trials for ATN-161.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Acute Kidney Injury, HIV Infections, and Renal Insufficiency. The leading clinical trial sponsors are University of North Carolina, Chapel Hill, Attenuon, and National Institute of Mental Health (NIMH).
There are one hundred and twenty-two US patents protecting this investigational drug and one international patent.